<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03813277</url>
  </required_header>
  <id_info>
    <org_study_id>3005031</org_study_id>
    <nct_id>NCT03813277</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy of DEXDOR in Pediatric Patients in ICU</brief_title>
  <acronym>Pedrux</acronym>
  <official_title>Open Clinical Trial to Evaluate Safety, Tolerability, and Efficacy of Dexdor for Sedation in Paediatric Patients in Intensive Care Settings. Multi-centre Trial in Russia for Marketing Registration of Dexdor.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open clinical trial to evaluate safety, tolerability, and efficacy of Dexdor for sedation in&#xD;
      paediatric patients in intensive care settings. Multi-centre trial in Russia for marketing&#xD;
      registration of Dexdor&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dexmedetomidine is in Russian currently approved for sedation only in adults; paediatric&#xD;
      experiences in the literature are in the form of small studies and case reports.&#xD;
&#xD;
      Dexmedetomidine may be useful in paediatric patients for sedation in a variety of clinical&#xD;
      situations. Based on literature analysis, dexmedetomidine may be potentially used in the&#xD;
      intensive care unit in pediatric patients who require sedation, either breath spontaneously&#xD;
      or require mechanical ventilation.&#xD;
&#xD;
      Dexmedetomidine is a newer sedative with little safety data in paediatrics, particularly for&#xD;
      therapy lasting longer than 48 h. Additional studies in paediatric patients are warranted to&#xD;
      further evaluate its safety and efficacy in all age ranges.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 21, 2017</start_date>
  <completion_date type="Actual">May 21, 2018</completion_date>
  <primary_completion_date type="Actual">May 21, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of efficacy of Dexdor for prolonged sedation in pediatric patients</measure>
    <time_frame>max 5 days</time_frame>
    <description>Time spent in target sedation range (RASS score )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Dexdor efficacy for prolonged sedation in pediatric patients</measure>
    <time_frame>max 5 days</time_frame>
    <description>Proportion of patients requiring rescue medication used for inadequate sedation (rescue-medication)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wake-up/discontinuation of sedation (if applicable)</measure>
    <time_frame>max 5 days</time_frame>
    <description>Wake-up/discontinuation of sedation (if applicable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to extubation.</measure>
    <time_frame>max 5 days</time_frame>
    <description>Extubation assessment (if applicable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first rescue medication</measure>
    <time_frame>max 5 days</time_frame>
    <description>Time to first rescue medication</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>max 5 days</time_frame>
    <description>Clinical safety of dexdor infusion</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>ICU Sedation</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 100microg/ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>infusion</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age from 12 to 17 years;&#xD;
&#xD;
          2. Clinical need for prolonged (&gt;24h) light to moderate sedation in patients with&#xD;
             spontaneous or artificial ventilation&#xD;
&#xD;
          3. Negative urine pregnancy test (for female patients);&#xD;
&#xD;
          4. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute severe intracranial or spinal neurological disorder due to vascular causes,&#xD;
             infection, intracranial expansion or injury; any other disorder where sedation&#xD;
             assessment is not reliable due to any neurological conditions;&#xD;
&#xD;
          2. Uncompensated acute circulatory failure;&#xD;
&#xD;
          3. Severe hypotension or hypertension&#xD;
&#xD;
          4. Severe bradycardia or tachycardia&#xD;
&#xD;
          5. A/V-conduction block II-III;&#xD;
&#xD;
          6. Severe hepatic impairment&#xD;
&#xD;
          7. Loss of hearing or vision, or any other condition which would significantly interfere&#xD;
             with the collection of study data;&#xD;
&#xD;
          8. Use of centrally acting alfa-2 agonists or antagonists in the period less than 5x&#xD;
             halflife between drug discontinuation and the time of randomisation;&#xD;
&#xD;
          9. Patients who have or are expected to have treatment withdrawn or withheld due to poor&#xD;
             prognosis&#xD;
&#xD;
         10. Patients receiving sedatives for therapeutic indications (e.g. epilepsy);&#xD;
&#xD;
         11. Patients allergic to dexmedetomidine and rescue medications&#xD;
&#xD;
         12. Hemodialysis and peritoneal dialysis;&#xD;
&#xD;
         13. Those requiring deep sedation or neuromuscular blocking agents;&#xD;
&#xD;
         14. Burn injuries and other injuries requiring regular anaesthesia or surgery;&#xD;
&#xD;
         15. History / family history of malignant hyperthermia;&#xD;
&#xD;
         16. Patients unlikely to be weaned from the ventilator during the study;&#xD;
&#xD;
         17. Patients with early-onset ventilator-associated pneumonia;&#xD;
&#xD;
         18. Any investigational drug within the preceding 30 days;&#xD;
&#xD;
         19. Any other reason which in the investigator's opinion would make it detrimental for the&#xD;
             subject to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andershan Lekmahnov, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Federal-Funded Educational Institution of</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State Federal-Funded Educational Institution of</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2019</study_first_posted>
  <last_update_submitted>January 22, 2019</last_update_submitted>
  <last_update_submitted_qc>January 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

